Teleflex Highlights Study involving ARROW® PICC with Chlorag+ard® Technology, Showing Significant Reduction in PICC-Related...
September 05 2014 - 09:00AM
Business Wire
Antimicrobial and Antithrombogenic Catheter is
Reported to Reduce Both CLABSIs and Treatment-Related Costs
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical devices for critical care and surgery, has announced
results of a new peer-reviewed study involving the ARROW®
PICC with Chlorag+ard® Technology, published in the Fall
2014 issue of the Journal of the Association for Vascular Access
(JAVA). The ARROW® PICC with Chlorag+ard® Technology
is the world's first and only antimicrobial and antithrombogenic
PICC.
The research, using the ARROW® PICC with
Chlorag+ard® Technology, determined that this kind of
Peripherally Inserted Central Catheter (PICC) was associated with a
nearly nine-fold drop in the rate of Central Line-Associated
Bloodstream Infections (CLABSIs). The peer-reviewed study was
conducted at Sharp Chula Vista Medical Center (SCVMC) in Chula
Vista, Calif.
The study was undertaken in part because the medical center’s
CLABSI rate had remained above the national benchmark, despite
comprehensive efforts to prevent these potentially deadly
infections. Use of an antimicrobial catheter in such circumstances
is recommended by the CDC and the Infusion Nurses Society.
In the study, concurrent data was collected from 260 patients
who received the ARROW® PICC with Chlorag+ard®
Technology. That data was then compared to retrospective data for
257 patients who had only received unprotected PICCs during the
previous year.
The results of the study showed a clear, positive impact from
the ARROW® PICC with Chlorag+ard® Technology. The 257
subjects in the non-interventional group had eight CLABSIs and an
infection rate of 4.18/1000 line days. The 260 subjects in the
interventional group had only one CLABSI and an infection rate of
0.47 infections/1000 line days.
In addition, a financial analysis showed that the ARROW®
PICC with Chlorag+ard® Technology reduced costs associated
with CLABSIs. Using the device enabled the hospital to avoid seven
CLABSIs during the six-month study period. Conservatively assuming
a treatment cost of $16,500 per infection, researchers calculated
that SCVMC saved $115,500 during the study period – an amount that
includes the added cost for the preventive PICCs. The study author
was Glenell Rutkoff, MSN, RN, CGRN, Manager Ambulatory and
Ancillary Services at SCVMC.
”We are excited about the results of this important study,” said
Jay White, President, Vascular Division of Teleflex. “It is well
supported in the literature that PICC-related infections among
inpatient populations are similar to those of acute non-medicated
(non-tunneled) CVCs and higher than those of acute medicated
(non-tunneled) CVCs.1 Also, for patients in the ICU, the risk of
PICC-related infections can be nearly double that of patients
outside of the ICU.2 In this era of healthcare reform, we know
hospitals are looking for solutions to reduce CLABSI rates. For all
these reasons, we are pleased to provide hospitals with
Chlorag+ard® Technology in an effort to reduce PICC-related
infections, improve hospital efficiencies and overall costs. This,
coupled with the fact that Chlorag+ard® Technology also
provides antithrombogenic benefits, allow us to provide solutions
to multiple complications associated with PICCs."
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical
devices for a range of procedures in critical care and surgery. Our
mission is to provide solutions that enable healthcare providers to
improve outcomes and enhance patient and provider safety.
Headquartered in Wayne, PA, Teleflex employs approximately 11,500
people worldwide and serves healthcare providers in more than 150
countries. Additional information about Teleflex can be obtained
from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, Arrow and Chlorag+ard are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates© 2014
Teleflex Incorporated. All rights reserved. MC-000480
References:
- Maki D et al. The risk of bloodstream
infection in adults with different intravascular devices: a
systematic review of 200 published prospective studies. Mayo Clin
Proc. 2006;81(9):1159-1171
- Ajenjo M et al. Peripherally Inserted
Central Venous Catheter-Associated Bloodstream Infections in
Hospitalized Adult Patients. Infect Control Hosp Epidemiol.
2011;32(2):125-130
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2023 to Mar 2024